awmsg logo



dasatinib (Sprycel®)


Reference No. 1514


Appraisal information

dasatinib (Sprycel®) 20 mg film-coated tablet
dasatinib (Sprycel®) 50 mg film-coated tablet
dasatinib (Sprycel®) 70 mg film-coated tablet
dasatinib (Sprycel®) 80 mg film-coated tablet
dasatinib (Sprycel®) 100 mg film-coated tablet
dasatinib (Sprycel®) 140 mg film-coated tablet


Company: Bristol-Myers Squibb Pharmaceuticals Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 06/02/2019
AWMSG meeting date: 13/03/2019
   
   
Submission Type: Limited Submission
Status: In progress
Advice No: Not available
Ratification by Welsh Government: Not available

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

Indication

Treatment of paediatric patients weighing > 10 kg with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in chronic phase (Ph+ CML‑CP) or Ph+ CML‑CP resistant or intolerant to prior therapy including imatinib
AWMSG Secretariat Appraisal Report (ASAR)
Download
Preliminary Appraisal Recommendation (PAR)
Download
Company Response to the Preliminary Appraisal Recommendation (CR PAR)
Download